Healthcare


 Is the Recent Performance of Sonic Healthcare Limited (ASX:SHL) Stock Influenced by Its Financial Health?

Is the Recent Performance of Sonic Healthcare Limited (ASX:SHL) Stock Influenced by Its Financial Health?

January 21, 2025 11:32 PM AEDT| By Team Kalkine Media

Is the Recent Performance of Sonic Healthcare Limited (ASX:SHL) Stock Influenced by Its Financial Health?

 SDI Limited Financial Strength Amid Market Fluctuations

SDI Limited Financial Strength Amid Market Fluctuations

January 21, 2025 05:31 PM AEDT| By Team Kalkine Media

SDI Limited Financial Strength Amid Market Fluctuations

 Respiri Acquires Orb Health Inc. to Strengthen U.S. Market Position

Respiri Acquires Orb Health Inc. to Strengthen U.S. Market Position

January 21, 2025 12:04 PM AEDT| By Team Kalkine Media

Highlights,Acquisition of Orb Health:,Respiri has successfully acquired,Orb Health Inc.,for,US$9 million,in shares, marking a significant milestone in its expansion into the,U.S. connected and chronic care health market,.,Additional investment from O...

 Lumos Diagnostics (ASX:LDX) Shares Up 31%, Business Prospects Need Improvement

Lumos Diagnostics (ASX:LDX) Shares Up 31%, Business Prospects Need Improvement

January 21, 2025 11:36 AM AEDT| By Team Kalkine Media

Lumos Diagnostics (ASX:LDX) Shares Up 31%, Business Prospects Need Improvement

 Insiders Forfeit AU$265k with Emyria Stock Declining to AU$0.03

Insiders Forfeit AU$265k with Emyria Stock Declining to AU$0.03

January 21, 2025 11:35 AM AEDT| By Team Kalkine Media

Insiders Forfeit AU$265k with Emyria Stock Declining to AU$0.03

 A year ago, purchasing shares in Ansell (ASX:ANN) would have yielded a 49% return.

A year ago, purchasing shares in Ansell (ASX:ANN) would have yielded a 49% return.

January 21, 2025 11:30 AM AEDT| By Team Kalkine Media

Highlights:,Ansell Limited (ASX:ANN) shares outperformed the market significantly over the past year.,Total shareholder return outpaces simple share price gains when dividends are included.,Insider buying and analyst forecasts may indicate further po...

 ASX Biotech Companies Focused on Early Cancer Detection

ASX Biotech Companies Focused on Early Cancer Detection

January 21, 2025 11:00 AM AEDT| By Team Kalkine Media

Pioneering Advances in Cancer Detection by ASX-Listed Biotechs

 Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position

Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position

January 20, 2025 01:43 PM AEDT| By Team Kalkine Media

Highlights,Orthocell,Ltd. (,ASX:OCC,) receives,a A,$3.18 million R&D tax refund, boosting its cash reserves to A$33 million.,The company is preparing for a US market entry with its innovative medical devices.,A strategic global expansion is underway,...

 EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.

EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.

January 20, 2025 11:00 AM AEDT| By Team Kalkine Media

EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.

 Optiscan (ASX:OIL) Initiates GI Study in Germany Using Its Initial Imaging Prototype

Optiscan (ASX:OIL) Initiates GI Study in Germany Using Its Initial Imaging Prototype

January 19, 2025 11:00 AM AEDT| By Team Kalkine Media

Optiscan Advances GI Imaging Technology with New Pre-Clinical Study

 Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?

Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?

January 18, 2025 01:32 PM AEDT| By Team Kalkine Media

Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?

 Lung Imaging Company Cyclopharm (ASX:CYC) Finds Success in the US Market

Lung Imaging Company Cyclopharm (ASX:CYC) Finds Success in the US Market

January 18, 2025 11:00 AM AEDT| By Team Kalkine Media

Cyclopharm's Strategic Expansion in the US Healthcare Market

 ASX Quarterly Health Summary: EZZ Scores Big, ReNerve's Initial Post-IPO Report

ASX Quarterly Health Summary: EZZ Scores Big, ReNerve's Initial Post-IPO Report

January 18, 2025 11:00 AM AEDT| By Team Kalkine Media

EZZ Life Science and Microba Report Strong Q2 FY25 Growth

 How Will OPT-302 Transform the Future of Eye Disease Treatment?

How Will OPT-302 Transform the Future of Eye Disease Treatment?

January 18, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,Opthea's lead drug, OPT-302, shows significant promise as a new treatment for challenging eye diseases, such as wet AMD and DME.,If Phase III trials yield positive results, OPT-302 could open a large market opportunity, with peak sales by...

 Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies

Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies

January 17, 2025 04:30 PM AEDT| By Team Kalkine Media

Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies

 Telix Pharmaceuticals (ASX:TLX) Gains After EU Approval for Illuccix in Prostate Cancer Treatment

Telix Pharmaceuticals (ASX:TLX) Gains After EU Approval for Illuccix in Prostate Cancer Treatment

January 17, 2025 12:37 PM AEDT| By Team Kalkine Media

Highlights,Telix,Pharmaceuticals (,ASX:TLX,) shares jump following European approval.,Illuccix,, the prostate cancer diagnostic agent, gets the green light.,The,stock,has risen by over 140% in the past year.,Telix Pharmaceuticals (ASX:TLX), a Melbour...

 ResMed Gains Limelight as Goldman Sachs Sets Bullish Target

ResMed Gains Limelight as Goldman Sachs Sets Bullish Target

January 17, 2025 11:39 AM AEDT| By Team Kalkine Media

Highlights,Strong Performance:,ResMed shares have surged 44% in the past 12 months, showing robust investor confidence in the sleep disorder treatment company.,Analyst Endorsement:,Goldman Sachs has initiated coverage with a,buy,rating and a price ta...

 Telix Pharmaceuticals Secures European Authorisation for Prostate Cancer Imaging Agent Illuccix®

Telix Pharmaceuticals Secures European Authorisation for Prostate Cancer Imaging Agent Illuccix®

January 17, 2025 11:31 AM AEDT| By Team Kalkine Media

Highlights,European Approval for Illuccix®:,Telix Pharmaceuticals received a positive decision on its Marketing Authorization Application (MAA) for Illuccix® across 18 European Economic Area (EEA) member states.,Breakthrough in Prostate Cancer Imagin...

 Immuron Reports Strong Sales Growth for Travelan® Across Global Markets

Immuron Reports Strong Sales Growth for Travelan® Across Global Markets

January 17, 2025 11:30 AM AEDT| By Team Kalkine Media

Highlights,Global Sales Surge:,Travelan® global sales reached AUD $2.5 million in the December 2024 Quarter, up 70% from the prior quarter and 249% compared to the same period in 2023.,Australian Market Leads Growth:,Australian sales increased 90% qu...

 Telix maintains steady growth, while Pro Medicus secures another contract.

Telix maintains steady growth, while Pro Medicus secures another contract.

January 17, 2025 11:00 AM AEDT| By Team Kalkine Media

Telix maintains steady growth, while Pro Medicus secures another contract.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.